Although this is one of the largest studies of breast cancer among young women, a limitation is the modest number of cases for rarer tumour subtypes, especially HER2-overexpressed (5% of all cases), potentially reducing the statistical power of analyses for these tumour subtypes. Here, ERBB2 is linked to breast cancer.